NorthShore University HealthSystem, Ambry Genetics announce new prostate cancer risk test

IMAGE: Brian Helfand, MD, PhD, a urologist with NorthShore’s Center for Personalized Medicine. view more 

view more 

(Evanston, IL) – September 25, 2018 – NorthShore University HealthSystem’s (NorthShore) Center for Personalized Medicine and Ambry Genetics Corporation (Ambry), announced today the launch of AmbryScore for prostate cancer risk.

AmbryScore is the first commercially available polygenic risk score designed to estimate a man’s individualized risk for prostate cancer. The test provides a prostate cancer risk assessment calculation based on the combined effects of 72-prostate cancer-associated single nucleotide polymorphisms (SNPs). Knowing an individual’s prostate cancer risk allows for earlier intervention through screening, preventative, and diagnostic measures aimed at early detection, which has been shown to improve patient outcomes.

The American Cancer Society estimates in 2018 there will be nearly 165,000 new cases of prostate cancer diagnosed and 30,000 deaths from the disease, indicating the need for better tools to aid in early intervention.

The test is ordered through an individual’s healthcare provider, where a sample is collected with the option to select the test as an add-on to select hereditary cancer panels. Due to the population-specific nature of SNPs, a patient must be of Northern European ancestry to be eligible for the test.

Originally developed


Article originally posted at

Click here for the full story

CategoryAggregator News

Privacy Policy / Terms Of Use

Powered by MMD